以化学信息学为基础,对人类癌症的酸化RET氨酸激酶抑制剂进行鉴定
Md Enamul Kabir Talukder1,2, Md Aktaruzzaman1,3, Noimul Hasan Siddiquee1,4
1Laboratory of Computational Biology, Biological Solution Centre, Jashore, Bangladesh.
Frontiers in chemistry
|August 1, 2024
概括
研究人员确定了四种新型化合物,其向的是转染过程中重新排列的 (RET) 瘤基因,这是多种癌症的关键驱动因素. 这些化合物显示出抑制RET氨酸激酶活性的潜力,并可能导致新的癌症治疗方法.
科学领域:
- 在瘤学瘤学.
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 在转移过程中重新排列的 (RET) 瘤基因在各种癌症的发展和进展中发挥着关键作用,包括肺癌,甲状腺癌,胰腺癌,乳腺癌和结直肠癌.
- RET信号的失调是瘤发生的一个重要因素,强调了针对性治疗策略的必要性.
- 识别能够有效抑制RET活性的新型化合物对于开发新的癌症治疗方法至关重要.
研究的目的:
- 发现和评估潜在的化合物,以RET瘤基因为目标.
- 评估这些化合物的有效性,以抑制不同类型癌症的癌症进展.
主要方法:
- 利用ZINC数据库的高通量虚拟选 (HTVS) 来识别初始化合物候选者.
- 采用分子对接和MM-GBSA溶解来评估结合亲缘关系和预测化合物稳定性.
- 进行了分子动力学 (MD) 模拟,以进一步验证具有目标受体的有希望化合物的稳定性.
主要成果:
- 在17万多种化合物中,HTVS发现了2550种潜在化合物.
- 分子对接研究确定了10种具有有利结合分数的化合物.
- MM-GBSA和MD模拟证实了四种特定化合物的稳定性和潜在的抑制活性 (CID 95842900,CID 137030374,CID 124958150,CID 110126793).
结论:
- 这四种已识别的化合物显示出抑制酸化RET (pRET) 氨酸激酶活性的潜力.
- 这些化合物代表了开发针对RET驱动癌症的新型治疗剂的有希望的候选人.
- 需要进一步的研究来探索这些化合物在癌症治疗中的临床应用.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Receptor Tyrosine Kinases
12.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


